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Research using animal models of asthma is currently dominated by mouse models. This
has been driven by the comprehensive knowledge on inflammatory and immune reactions
in mice, as well as tools to produce genetically modified mice. Many of the identified thera-
peutic targets influencing airway hyper-responsiveness and inflammation in mouse models,
have however been disappointing when tested clinically in asthma. It is therefore a great
need for new animal models that more closely resemble human asthma.
The guinea pig has for decades been used in asthma research and a comprehensive table of
different protocols for asthmamodels is presented. The studies have primarily been focused
on the pharmacological aspects of the disease, where the guinea pig undoubtedly is superior
to mice. Further reasons are the anatomical and physiological similarities between human
and guinea pig airways compared with that of the mouse, especially with respect to airway
branching, neurophysiology, pulmonary circulation and smooth muscle distribution, as well
as mast cell localization and mediator secretion. Lack of reagents and specific molecular
tools to study inflammatory and immunological reactions in the guinea pig has however
greatly diminished its use in asthma research.
The aim in this position paper is to review and summarize what we know about different
aspects of the use of guinea pig in vivo models for asthma research. The associated aim is
to highlight the unmet needs that have to be addressed in the future.
Introduction
Respiratory diseases have a complex pathobiology where interplay between inhaled matter, local host
defense in the airways, and systemic immunological and endocrine responses lead to different disease
phenotypes. Although components in the different disease processes may be investigated in human cell
and tissue models, the integrated understanding of the relative importance of implicated disease mecha-
nisms can only be established in the intact body. Experimental medicine approaches in healthy humans
or patients with disease provide the highest degree of evidence in the testing of hypotheses for physiolog-
ical, pharmacological or pathological reactions. Nevertheless, before it is ethical to embark on studies in
humans, understanding of mechanisms, pharmacodynamics, pharmacokinetics and safety must be estab-
lished in valid experimental models.
It goes without saying that the foremost criterion for the use of animal models to investigate questions
concerning human physiology or disease pathobiology is that the model is of relevance to the human
disease or the specific reaction that is addressed. Over the past few decades, the development of genetically
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modified mice strains has introduced unprecedented opportunities to define mechanisms and pathways by over-
expression or deletion of proteins mediating or regulating a variety of processes. There are a number of discoveries
in such studies that have been important for the understanding of, in particular, the immune system [1]. In respira-
tory medicine, and particularly for airway diseases such as asthma and COPD, the mouse models have however been
disappointing and led to few, if any, new discoveries with relevance to the modeled disease entities in humans [2,3].
Likewise, animal experiments are often required to follow-up and analyze in greater detail observations in patients.
In animal welfare interests (3Rs: for replace, reduce and refine animal use), several alternatives for animal experimen-
tation by using human in vitro models have been developed, ranging from very simple models using human cells in
mono- or co-culture, whole tissue explants and new tissue engineering approaches [4]. However, when studying such
a complex disease as asthma involvingmultiple genetic and environmental influences whose interactions result in in-
tricate systemic activation and multifactorial alterations of pulmonary function [5], in vivo animal experimentation
is presently unavoidable. The development of refined asthma models in guinea pigs have great potential to replace
irrelevant mouse models and thereby reducing the number of animals needed.
For this reason and relating to the fact that discoveries using guinea pig models already in the early 20th century
identified mechanisms that have been directly translated into human physiology or pathology, the Centre for Allergy
Research Highlights Asthma Markers of Phenotype (ChAMP) project at Karolinska Institutet held a workshop on
guinea pig models in the late spring of 2017. The meeting was followed by a process leading to the compilation of
this review article summarizing the state-of-the-art concerning the use of guinea pigs for studies of airway diseases
including asthma, COPD, and chronic cough. In this review we have focused on the in vivo models, although very
interesting in vitro findings also have been performed, e.g. using isolated guinea pig airways.We hope that researchers
in academia and industry will benefit from this first very comprehensive account of fundamental aspects on the use
of guinea pigs for respiratory research.
Guinea pig models of asthma: what have we learned?
Immediate hypersensitivity reaction of the lung was discovered in guinea pigs more than 100 years ago [6]. Preclin-
ical pharmacological studies performed in guinea pigs have proven indispensable to the development of therapies
for a wide range of respiratory diseases [7]. The relevance of these therapies to respiratory diseases was often first
described in studies performed in guinea pigs. These include β2-selective adrenoceptor agonists, anticholinergics,
anti-IL-5, cysteinyl leukotriene (CysLT1) receptor antagonists and 5-lipoxygenase inhibitors, all of which were first
shown efficacious in either in vitro studies using isolated guinea pig airway preparations, or in vivo in models of
allergen-induced inflammatory responses and/or agonist-induced bronchospasm. Long-acting β2 adrenoceptor ag-
onists and anticholinergics were also first characterized in studies performed in guinea pigs [8–17]. By the emergence
of transgenic technology and the development of species-specific immunological tools mouse models have nowa-
days become the standard for obstructive airways disease, despite some serious physiological and pharmacological
shortcomings. As a major drawback, the mediators that regulate airway smooth muscle (ASM) tone and ultimately
determine airway responsiveness are appreciably different from those in humans as well as guinea pigs, questioning
their usefulness for investigating functional clinical end points in asthma [7,18,19]. For example, early asthmatic re-
sponses and airway hyperresponsiveness (AHR) are usually only induced after repeated allergen challenges, whereas
late asthmatic reactions are rarely observed [20]. With only few exceptions, these responses have proven to be crucial
for demonstrating clinical efficacy of existing and investigational drugs [21]. By contrast, measurements in sensitized
guinea pigs have demonstrated allergen-induced dual asthmatic reactions [18,19,22–28], AHR [18,19,25,28–32] and
eosinophilic airway inflammation [18,19,22–24,26–28,30–32] similar as in patients upon single allergen challenge
[18,19,22–32]. In a comprehensive study, using permanently instrumented, unanesthetized and unrestrained guinea
pigs with continuous and prolonged online monitoring of lung function by pleural pressure measurement, relation-
ships among allergen-induced early and late airway obstructions, AHR after both reactions and airway inflammation
could be performed within the same animal and were shown to be strikingly similar to those observed in asthmatic
patients, both in a qualitative and in a quantitative sense [18,26].
Although inflammation and structural remodeling contribute to asthma pathogenesis, majority of studies focus
on the inflammatory reactions [33]. Targeting of inflammation alone has not provided disease modification and thus
there is a need for airway remodeling to be addressed for future therapeutic strategies. Likewise, airway remodeling
may be induced in guinea pigs. Already in the 1930s it was observed that repeated antigen challenges of guinea pigs
over several weeks induced structural changes in the airways, including goblet cell hyperplasia and increased ASM
mass ([34], discussed in [35]), observations that have been confirmed and extended inmore recent studies [32,36–40].
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Due to the vast variety of biological and biophysical processes that may be involved in the regulation of airway
responsiveness, the mechanisms underlying AHR in asthma are only partially understood and animal models and in
vitro model systems are indispensable to unravel these mechanisms at the cellular and molecular level [19]. In this
regard in vivo and ex vivo studies in guinea pig models of allergic asthma, particularly focused on the regulation of
ASM function, have shown great translational value and supported the discovery and development of new therapeutic
options, some of which are discussed below.
Airway pharmacology
Similarities with human biology
Guinea pigs fulfill the primary and important assumption made when using animal models of human respiratory
diseases for drug discovery, namely, that the physiological, immunological and/or signal transduction mechanisms
controlling the specific processes contributing to human pathology are recapitulated in the chosen animal system
[7]. For example, in studies of the immediate type (allergic) hypersensitivity reaction in the airways, the end organ
effects attributed to allergen-induced mast cell activation include ASM contraction, mucus secretion, plasma exuda-
tion from airway mucosal postcapillary venules, an eosinophilic cellular infiltrate and an associated increase in AHR.
These acute effects induced by allergen in the human airways are mediated by histamine H1 receptor and leukotriene
cysLT1 receptor activation [41–44]. Guinea pig airway responses to acute allergen challenge mimic exactly that seen
in humans and similarly involve the activation of H1 and cysLT1 receptors [45–47]. Subacute effects of the allergic
response in human airways and lungs depend in part upon airway defensive reflexes such as parasympathetic, cholin-
ergic reflex bronchospasm resulting from muscarinic M3 receptor activation on ASM, as well as cough and other
respiratory reflexes and sensations. Finally, airway neural control in guinea pigs is very similar to that described in
humans [48].
Limitations of mice
In contrast with guinea pigs, mice have limited predictive value formany of the organs that are fundamental to human
respiratory disease pathogenesis [7]. For example, while allergen-induced bronchospasm in humans and in guinea
pigs depends primarily on histamine H1 and leukotriene CysLT1 receptor activation in ASM, neither histamine nor
the cysLTs induce ASM contraction in vitro nor bronchospasm in vivo in mice. Rather, bronchospasm evoked by
acute allergen challenge in mice and rats depends upon mast cell-derived serotonin release and the activation of
airway parasympathetic nerves [49–52]. Human and guinea pig mast cells store or release little if any serotonin,
and this biogenic amine is without effect on isolated human ASM [53,54]. Murine airways also lack the bronchial
circulation andmucus glands readily identifiable in the airways of humans and guinea pigs [55,56] and, unlike humans
and guinea pigs, murine airways have no inhibitory innervation of their ASM to counteract the physiologic effects
of acute asthmatic attacks [48]. Even the subtypes of β-adrenoceptors that can be activated therapeutically to reverse
acute asthmatic bronchospasm differ in mice compared with either humans or guinea pigs [57].
Agonists and receptors
A second assumption or expectation of animal models of human respiratory disease is that the pharmacological
properties of the autacoids and receptors involved closely match those properties in human cells and tissues. This
expectation has been established in guinea pigs [7]. Among the autacoid and neurotransmitter receptors that can
evoke ASM contraction in human airways when activated, including muscarinic M3, neurokinin NK2, leukotriene
cysLT1, endothelin ETB receptors and thromboxane/prostanoid TP receptors, these also evoke ASM contraction in
vitro in preparations of guinea pig airways, and bronchospasm in vivo in guinea pigs. Essentially all drugs developed
to target the cysLTs in the airways were developed preclinically in studies performed in guinea pigs [58–65]. Physi-
ologically, stimuli evoking reflex bronchospasm in humans such as bradykinin similarly evoke reflex bronchospasm
in guinea pigs [48]. These contractions and parasympathetic reflexes can be fully reversed by agonists for β2 adreno-
ceptors, peptide transmitters such as vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating
polypeptide (PACAP) and nitric oxide (and other nitrosylating activators of soluble guanylate cyclase). The relax-
ant responses evoked by these transmitters and therapeutic agents depend upon formation of the cyclic nucleotides
cAMP and cGMP, and in both humans and guinea pigs, inhibitors of cAMP and cGMP specific phosphodiesterases
(PDE3, PDE4 and PDE5) expressed by ASM potentiate these relaxant responses by delaying cyclic nucleotide in-
activation. Furthermore, for the development of the novel dual PDE3/4 inhibitor RPL-554 [66], the efficacy was
evaluated in guinea pigs [67], and confirmed in humans [68], but never tested in a mouse. Thus, the development
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Figure 1. The potency and efficacy of receptor antagonists determined in bioassays performed in guinea pig tissues is
highly predictive of their potency and efficacy in human tissues
The pA2/pKb values for antagonists targeting muscarinic M3, leukotriene cysLT1, neurokinin2 (NK2), thromboxane TP, β2 (b2)
adrenoceptors and endothelin B (ETB) receptors in guinea pig tissues assays (primarily guinea pig trachea) were highly correlated
with their measured pA2/pKb values in human tissue assays (primarily human intrapulmonary bronchi). When multiple pA2/pKb
values were reported in the literature, the average responses from these studies are depicted. The figure is constructed using data
and the relevant references obtained from [7].
of new drug classes for the treatment of respiratory diseases further support the usefulness of guinea pigs. More-
over, neither histamine nor the cysLTs are able to evoke bronchospasm in mice, and neurokinins surprisingly evoke
epithelium-dependent ASM relaxation in murine airways [69].
Also, worth noting is the near perfect correlation between antagonist potencies at receptors relevant to respiratory
disease in guinea pigs with their counterparts in preparations of human airways or cells (Figure 1). This latter obser-
vation may be attributable to the high identity documented through BLAST sequence comparisons of the relevant
guinea pig genes and their human counterparts (85–89% identity for M3, NK2, cysLT1, ETB and β2 adrenoceptors
(mean = 86.8 +− 0.8% identity); https://www.ncbi.nlm.nih.gov/nuccore/). Identity of murine orthologs to these hu-
man genes is reasonable but demonstrably lower than that observed in guinea pigs (82–86% identity (mean= 84.2+−
0.7% identity); P<0.03). Moreover, as mentioned, the pattern of expression for these receptors in the airways clearly
differs inmice comparedwith either humans or guinea pigs. Such differences in gene expression also likely account for
the unique pharmacology of voltage-gated sodium channel regulation of murine ASM tone, while human and guinea
pig airways appear to have comparable patterns of sodium channel expression in airway parasympathetic nerves [70].
Although the predictive value of guinea pigs for preclinical drug discovery in respiratory medicine has been clearly
established, there are several notable differences and limitations to using this species for modeling human airway
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Figure 2. Upper respiratory tract, paramedian section
1: naris, 2: ventral conchae, 3: dorsal conchae (ossa turbinalia I-IV), 4: os incisivum, 5: mandibula, 6: tongue, 7: soft palate, 8: larynx,
9: epiglottis, 10: trachea, 11: esophagus, 12: brain. Picture prepared by Eva Stoffels based on anatomical dissections.
disease [7]. These include the expression of neuropeptides in the peripheral terminals of airway C-fibers (producing
axonal reflexes in the airways that are not observed in humans), expression of NK1 receptors and a CysLT2-like
receptor in ASM (in addition to NK2 and cysLT1 receptors), and the involvement of receptors for IgG1 in addition to
IgE in mast cell activation by allergen. An additional limitation is the minimal capacity for genetic manipulation in
guinea pigs, an approach that adds considerable utility to murine models of lung disease.
The respiratory system
Anatomy and physiology
Guinea pigs and humans display similar patterns of AHR [71,72]. Yet there are essential anatomical differences be-
tween a guinea pig and a human respiratory tract, which must be taken into account when considering guinea pigs
as a model for human respiratory hypersensitivity. A simplified scheme of the upper respiratory tract of a guinea
pig is shown in Figure 2. The most striking anatomical feature is the large soft palate flap located rostrally to and
overlapping the epiglottis. The palatal ostium is very tight. This makes guinea pigs obligate nasal breathers, which
has several consequences for experimental procedures. For example, endotracheal intubation is difficult because of a
risk of traumatic injury to the soft tissues. Furthermore, administration of substances acting on the nasopharynx (e.g.
acetylcysteine) through the oral route is not efficient. The trachea in an adult animal is approximately 35-mm-long;
the bifurcation is located between the second and third ribs. An anatomical view of the ventral surface (facies me-
diastinalis) is depicted in Figure 3. There are seven lung lobes, three right and two left, and two smaller accessory
lobes located ventrally. In contrast with the monopodial branching of the bronchial tree in mice, both the guinea pig
and human bronchial tree have dichotomous branching. However, the branching of a guinea pig is different from
that of a human. In humans, the two principal bronchi undergo bifurcations into numerous interlobar bronchi that
bifurcate further in intralobular bronchi, bronchioles and respiratory bronchioles. In guinea pigs, the two principal
bronchi proceed toward the largest lobes (right and left caudal lobes). There are much less bifurcations than in hu-
mans – there is only one distinct interlobar bronchus per lobe, and intralobular bronchi depart from each interlobar
bronchus laterally at an angle of approximately 90 degrees. The right principal bronchus is positioned more ventrally
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Figure 3. Anatomy of the guinea pig lung (left) and a scheme of the bronchial tree (right)
1–3: Lobus dexter cranialis, medius and caudalis, respectively. 4–5: lobus sinister cranialis, pars cranialis and caudalis. 6: lobus
sinister caudalis. 7–8: lobus accessorius sinister and dexter. 9: trachea. 10: impressio cardiaca. 11: aa and vv pulmonales. Pictures
prepared by Eva Stoffels based on anatomical dissections.
than the left one (because of impressio cardiaca). Therefore, aspiration of bacteria, foreign bodies, allergens etc., is
more likely to affect the right caudal lobe.
Guinea pig lung parenchyma is very delicate and lacks connective tissue. For example, there are no intralobular
septa. This allows efficient collateral ventilation on one hand, but it also makes the tissue prone to injury during me-
chanical ventilation or performing bronchoalveolar lavage (BAL) [72]. The cellular composition of guinea pig airways
differs from other animals. The bronchi are heavily muscled which is comparable with humans, but markedly differ
from with other species, especially mice which lack ASM below the first few bronchial generations [73]. There are
strikingly many goblet cells, producing mucous and not serous secretions. In the terminal bronchioles, Club cells are
most prominent (approximately 73%). The alveoli are dominated by type I pneumocytes, but in response to stimu-
lation or irritation, type II cells (producing surfactant) increase in numbers. The mast cells are largely located in the
smooth muscle layer but also present in the parenchyma. This can be compared with mice where mast cells mainly
are present in trachea, with very few located in the lungs. Although the alveoli contain numerous freely migrating
macrophages, phagocytosis is primarily performed by neutrophils that extravasate into the alveoli.
Lung physiological measurement
While there are fundamental differences between mice and guinea pigs in terms of airway tree anatomy, it turns out
that pretty much all lungs can be fitted with the same mathematical model relating structure to function because
lungs obey scaling laws across species [74] (Figure 4). This is good news, not only for the animal scientist but also for
the clinician because this means that it is possible to use the broadband forced oscillation technique (FOT) in both
animal studies and in human studies and interpret the data in a similar manner across species boundaries allowing
for translational studies [75–77]. Used to its fullest power FOT allows the partition of the result into responses in
the conducting airways compartment, and in the tissue compartment [78]. This is achieved by fitting a mathematical
model of the respiratory system to the impedance of the lung and solving for parameters that have logical and realistic
physiological properties, e.g. Newtonian resistance (Rn), tissue resistance (G) and lung elastance (H) [79–83].
There are very few published studies in guinea pigs using the full power of broadband FOT, but based on published
analyses there is every reason to believe that the respiratory system of the guinea pig will behave in a similar way as in
any other laboratory animal [74]. Allergic guinea pigs display characteristic changes in AHRwhen exposed tometha-
choline with increases in Rn, G andH, commensurate with elevations in lung lavage eosinophils and neutrophils [83]
supporting previous studies where glucocorticoids, xanthines, anti-histamines and β2 adrenoceptor agonists have
been shown to have positive effects on the guinea pig lung phenotype [84–88]. It is interesting to note that younger
guinea pigs appear to be more sensitive to the sensitization allergen than older animals [89], suggesting that guinea
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Figure 4. Parameters of the constant-phase model fitted to respiratory system impedance data of mice (n=11), rats (n=8),
guinea pigs (n=5) and rabbits (n=6) as a function of PEEP
Values are normalized to BW and represent means +− SE. NR, normalized Newtonian resistance; NI, normalized inertance; NGti,
normalized tissue damping; NHti, normalized tissue elastance; α = (2/π)arctan(Hti/Gti); η, hysteresivity. (Reproduced from [74] with
permission from the publisher).
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pigs might be a model for age-dependent longitudinal studies. Sensitized guinea pigs have a strong response to al-
lergen that can be modified to various degrees by inhibiting histamine, cyclooxygenases and CysLTs, demonstrating
mast cell involvement in the response [90]. Mast cell-dependent responses in mice have rarely been demonstrated
and they do not appear in the lung unless a vigorous sensitization protocol is employed [80].
Guinea pig lungs, on the other hand, have a significant number of mast cells [91] and will respond with a rapid
bronchoconstriction that is antagonized with either anti-histamines [92,93] or sodium cromoglycate [84] suggesting
that mast cell degranulation is responsible for the response. Sensitized guinea pigs have also been shown to have a
late response, hours after an allergen challenge, similar to what patients with asthma can experience [18,22–28].
FOT is quickly becoming an important tool in assessing lung function in patients, both in research and clinical
practice, and like animal FOT it can elucidate effects in the smaller airways thus making it a better tool for early diag-
nosis of lung disease [94]. Using broadband FOT allows for detailed examination of the respiratory system, separating
effects in the central vs. smaller airways, and using the same technique in both animals and humans will allow us to
extrapolate physiological findings from one species to the other and likely improve outcome in drug research and
eventually in patient care.
Unrestrained plethysmography has been used as a technique implying to measure lung function in guinea pigs
[95]. However, it has been demonstrated in the mouse, and theoretically, that only when the airways are severely
constricted does the airway resistance contribute to the signal of the main parameter, the enhanced pause (Penh). As
most small animals are obligate nose breathers, any swelling or other obstruction of the nasal passage is very likely to
have an impact on the Penh. In addition, stimulation of irritant receptors like the J-receptor can have profound effects
on the ventilatory pattern [96]. Thus, neither nasal obstruction nor CNS effects necessarily reflect on physiological
changes in the lung airways or lung parenchyma [97].
Model development
Immunological responses in different protocols
An experimental asthma model in the guinea pig was introduced in 1937 by Kallo´s and Pagel ([34], discussed in
[35]), since then, several protocols have been established. The field has a wide spectrum with respect to age of an-
imals, allergens, doses, route and frequency of allergen sensitization and challenges, which altogether influence the
‘asthmatic’ response. Table 1 summarizes some methods described in the literature, as well as the pathological fea-
tures found in those experimental models. Asthma severity and heterogeneity depends onmany factors that drive the
immune response, including genetics, age and gender. In guinea pig asthma models, albino outbred animals are the
most common laboratory strain, although other, including inbred strains, have been used in early studies [72,98,99].
Despite that the outbred nature of guinea pigs is a disadvantage in terms of genetic influence in the development of
experimental asthma, this is a suitable factor that contributes to modeling the heterogeneity of asthma in the guinea
pig.
The allergic response
OVA is the major antigen that has been used for experimental asthmamodels in guinea pigs. Single or repeated doses
of systemic OVA challenges mimic many asthma-related features (Table 1). It has been established that guinea pig
sensitization with low dose of OVA, i.e., 10 μg, promotes EARwith the induction of IgG1 and IgE synthesis [100,101],
whereas large dose of OVA, i.e., 100 μg, induces both EAR and LAR together with IgG1 production [40,100–102].
Nevertheless, it has also been described that following challenge with aerosolized OVA for one hour, guinea pigs
develop both EAR and LAR although the sensitizationwas performedwith a low dose ofOVA [28,103]. Notably, those
sensitization protocols were performed through intraperitoneal OVA injections. Instead, aerosol sensitization with a
low dose of OVA induces EAR and LAR with IgG1 and IgE production [104], and large dose generates EAR, AHR,
and eosinophilia [105,106]. Smith et al. demonstrated that the addition of a booster sensitization extends LAR and
increases theAHR, and eosinophil influx in guinea pigs sensitized [101].Moreover, the combination of intraperitoneal
and subcutaneous injections together with aerosol boosters cause EAR and OVA-specific IgG1 and IgE, besides AHR
and eosinophilia, but no LAR [39,107]. Several other compounds have been used as allergens in guinea pig models,
such as HDM extracts [108,109], purified proteins from mites [109], cockroach extracts [110–112], and trimellitic
anhydride dust [113,114]. However, there have been very few models developed and AHR was not established.
Strategies for induction of asthma models
The most common regimen for allergen exposure consists of a sensitization phase and a challenge phase (Table 1).
The sensitization phase is usually achieved by a single or repeated allergen dose; nonetheless, some protocols include
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Table 1 Protocols for guinea pig asthma models
Guinea pigs Sensitization phase Challenge phase Key features References
Initial dose Booster dose
Both sexes, Dunkin–Hartley,
250–300 g
Two sensitization procedures:
A) 0.1 ml of 5 mg OVA in
saline, i.p.
or
B) 0.5 ml of 0.1, 1, 10, or 100
μg OVA containing 100 mg
Al(OH)3 in saline, i.p.
Day 2
A) 0.1 ml of 10 mg OVA in
saline, i.p.
Day 14
1, 5, 10, 20, 40, 80, 160, or 320 μg/kg
OVA, i.v
Acute bronchoconstriction with low OVA doses (1–10 μg)
plus Al(OH)3 and IgG and IgE production, high OVA doses
induced only IgG production
(A) Less response than (B) method, higher doses of OVA
(10–320 μg/kg) to produce bronchospasm
(B) 0.1 μg OVA sensitization no response to the provocation
doses, 10 μg OVA induce an optimal bronchospasm
[100,122]
Male, Dunkin–Hartley, 450–500 g 1% OVA aerosol for 3 min Day 7
Same dose as initial day
Day 14
2% OVA aerosol for 5 min
*Mepyramine maleate (10 mg/kg, i.p.)
Allergen-induced bronchoconstriction: EAR (5 min–2 h) and
LAR (17 h)
Eosinophil and neutrophil increase in BALF
[115]
Male, 500–600 g 0.35 ml of 5% OVA into each
hind limb, intramuscular
injection
Day 6
Same dose as initial day
Week 5
1% OVA aerosols for 1 min
*Pyrilamine maleate (2 mg/kg, i.p.)
EAR and LAR
Eosinophil infiltration in lung and BALF
[171]
Female, Perl Bright-white, inbred
and specific pathogen-free,
300–350 g
Days 1–5
0.1 ppm SO2 for 8 h
Day 3
0.1% OVA aerosol for 45 min
Day 4 to 5
Same OVA dose as on day 3
Day 7
1% OVA aerosol for 5 min
Allergen-induced bronchoconstriction: EAR (30 min)
Eosinophils in BALF
Inflammatory cells in lung and epithelial damage
OVA-specific IgG1
[105,134]
Female, Cam–Hartley, 250–300 g
or 500–550 g
1% OVA aerosol with 4%
heat-killed Bordetella
pertussis vaccine in saline, for
10 min
Day 8
0.5% OVA aerosol for 5 min
Chronic model: OVA twice a week for
4–6 weeks
*Diphenhydramine (40 mg/ml, i.p.)
Allergen-induced bronchoconstriction
Tissue eosinophilia
AHR to acetylcholine
IgE and IgG1 production
[131–133]
Male, Hartley strain, specified
pathogen-free, 500–700 g
100 μg OVA and 100 mg
Al(OH)3 per ml saline, 0.5 ml
i.p and 0.5 ml divided over
seven s.c. injections in the
paws, lumbar regions and
neck
Weeks 4–8
0.1, 0.3 and 0.5% OVA aerosols for 3
min with 10-min intervals until
obstruction
Or
0.2% OVA aerosol for 15 min
EAR and LAR
AHR to histamine
Inflammatory cells influx
[26]
Male, Hartley strain, 200–250 g 1–2 mg OVA and 100 mg
Al(OH)3, i.p.
*Day 3 cyclophosphamide (30
mg/kg, i.p)
Week 4
0.01 mg OVA and 100 mg
Al(OH)3, i.p.
Week 7
10 mg/ml OVA aerosol for 60–90 s
*Diphenhydramine (20 mg/kg, i.p.) and
procaterol (0.1 mg/kg i.p.)
Allergen-induced bronchoconstriction
Cough
AHR to methacholine
Inflammatory cells in BALF and tissue
IL-4, IL-5, and IL-13
SP, PGE2, histamine, LTB4 and TXB2 in BALF
[127–130,172,173]
Male, Hartley strain, 250 g 0.5 ml of 0. OVA and 2 mg
Al(OH)3 in saline, i.p.
Week 2–4
Same dose as initial day, once a
week
Week 5
1 mg/kg OVA, i.v.
or
3 mg/ml OVA aerosol for 3min
*Mepyramine maleate (1 mg/kg, i.v.)
Allergen-induced bronchoconstriction: EAR (4 min)
Plasma leakage in the airways
[174,175]
Male, Dunkin–Hartley, specific
pathogen-free male, 300–550 g
0.5 ml of 2.5 mg OVA and 50
mg alum in saline, i.p.
Day 10
Same dose as initial day
Days 20 and 22
0.15 ml of 2% OVA intratracheal
*Pyrilamine maleate (10 mg/kg, i.p.)
Allergen-induced goblet cell degranulation
Neutrophil recruitment
Elastase release
[176]
Both sexes, C2BB/R-(inactivates
the C3aR) and C2BB/R+
(wild-type C3aR), inbred, 600-650
g
Days 0 and 7
0.5 ml of 10 μg OVA and 2
mg Al(OH)3 in saline, i.p.
Day 21
1% OVA aerosol in saline
Day 35
1% OVA aerosol for 8 min
*Pyrilamine (5 mg/kg, i.p.)
Reduced allergen-induced bronchoconstriction and AHR in
defective strain
Eosinophils infiltration in lung
[99]
Continued over
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Table 1 Protocols for guinea pig asthma models (Continued)
Guinea pigs Sensitization phase Challenge phase Key features References
Initial dose Booster dose
Male, Hartley strain 10 μg OVA and 100 mg
Al(OH)3 in saline, i.p.
Day 14
Same dose as initial day
Day 18
0.3, 1, 3, 10 mg/ml OVA aerosols for 3
min
Allergen-induced bronchoconstriction
AHR to histamine and methacholine
Inflammatory cells in BALF, blood, and tissue
Increase EPO activity
[117]
Male, Hartley strain, 300-400g 0.5 ml of 5% OVA, s.c. plus
0.5 ml OVA, i.p.
Day 7
Same dose as initial day
Day 15, 22 and 29
1% OVA aerosol for 3 min
*Mepyramine (10 mg/kg, i.p.)
**The animals fasted for 1 day before all
three inhalations
Allergen-induced bronchoconstriction: EAR and LAR (8 h)
AHR to methacholine
Eosinophilia in BALF
[138–140,177]
Male, Dunkin-Hartley, 200-250g 100μg OVA and 100 mg
Al(OH)3, i.p.
Day 5
Same dose as initial day
From day 15
Eight aerosols applied every 48 h for 1
h
0.01% OVA
*Mepyramine (30 mg/kg, i.p.)
Allergen-induced bronchoconstriction: EAR (0–6 h) and LAR
(6–24 h)
AHR to histamine
Inflammatory cells in lung tissue and BALF
Collagen deposition and mucus production
[40,101]
Male Dunkin–Hartley
200–300 g, male, specified
pathogen-free
100 μg OVA and 100 mg
Al(OH)3 per ml saline, 0.5 ml
i.p. and 0.5 ml divided over
seven s.c. injections in the
paws, lumbar regions and
neck
Day 5
Same dose as initial day
0.05, 0.1, 0.3, 0.5 and 0.7% OVA
aerosols for 3 min with 7-min intervals
until obstruction, once weekly for 12
consecutive weeks, starting 4 weeks
after sensitization
Enhanced ASM mass and contractility
Subepithelial fibrosis
Goblet cell hyperplasia
Mucus gland hypertrophy
Airway eosinophilia
Enhanced IL-13 in lung homogenate
AHR to methacholine
[37,178]
Male, Hartley strain, 4–7 weeks
old
1% OVA aerosol for 10min Days 2–7
Same dose as initial day
One week after final sensitization
2% OVA aerosol for 5 min
*Metyrapone (10 mg/kg, i.v.)
*Pyrilamine (10 mg/kg, i.p.)
Allergen-induced bronchoconstriction: EAR (1 min) and LAR
(4–8 h)
AHR to acetylcholine
Inflammatory cells in BALF
[106]
Male, Dunkin–Hartley, 350–400 g 0.5 ml of 60 μg/ml OVA and 1
mg/ml Al(OH)3 in saline, i.p.
and 0.5 ml s.c.
Day 8
3 mg/ml OVA aerosol for 5 min
From day 15
Twelve OVA aerosols applied every 10
days for 1 min
1 mg/ml OVA in the first and 0.5 mg/ml
in the subsequent challenges
Allergen-induced bronchoconstriction: EAR (20 min)
AHR to histamine
OVA-specific IgG1 and IgE
Inflammatory cells in lung tissue and BALF
Collagen deposit in airway
TNF-α, histamine, TXA2, and leukotrienes in BALF
[39,107,179]
Male, TRIK tribe strain, 150–350 g 1 ml of 5 mg OVA and 1 mg
(AlOH3), i.p. and 1 ml s.c.
Days 4–21
0.1 ml of 5 mg OVA, i.p. every 3
days
Days 16–21
1% OVA aerosol
Allergen-induced bronchoconstriction
Cough
Tracheal smooth muscle reactivity in vitro
AHR to histamine and acetylcholine
IL-4, IL-5, IL-13, and TNF-α in BALF
Lung infiltrated by eosinophils and mast cells
[137]
Male, Dunkin–Hartley, specific
pathogen-free, 300–500 g
100 μg OVA and 100 mg of
Al(OH)3 in saline, i.p.
Day 14
Same dose as initial day
Days 18–29
0.5% OVA aerosol daily for 10 min
Histamine and acetylcholine-induced bronchospasm
Inflammatory cells in BALF, blood, and tissue
TNFα, IL-4, IL-5, and IL-6 in serum and BALF
[180]
Male, TRIK tribe strain, 150–350 g 1% OVA, 0.5 ml i.p. and 0.5
ml s.c.
Day 3
1% OVA, 1 ml i.p.
Days 14 and 21 1% OVA aerosol for 30
s
Allergen-induced bronchoconstriction
AHR to histamine
Inflammatory cells in BALF
[181]
Male, Dunkin–Hartley, specific
pathogen-free male, 350–500 g
Days 1, 4, 7, 10, 13 (1 mg/ml)
Days 16,19, 22 (2.5 mg/ml)
Days 25, 28 (5 mg/ml)
Days 31, 34 (10 mg/ml)
OVA aerosols for 15min
Allergen-induced bronchoconstriction
AHR to methacholine
IL-13 and TNF-α mRNA expression in lung
Increase in ASM, subepithelial collagen deposition and
mucus production
Inflammatory cells infiltration in lung
Eosinophils in BALF
[143,182]
Continued over
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Table 1 Protocols for guinea pig asthma models (Continued)
Guinea pigs Sensitization phase Challenge phase Key features References
Initial dose Booster dose
Female, Hartley strain, specific
pathogen-free, 1 month of age
10 mg/kg OVA, i.p. Day 3
Same dose as initial day
Day 21 parainfluenza virus l, i.n.
Day 45: 0.5% OVA aerosol for 20 s
Day 70: re-exposed to parainfluenza
virus l, i.n.
AHR to histamine
Eosinophilic airway inflammation
[183]
Male, Hartley strain, 200–300 g 1 ml of 150 mg OVA and 100
mg Al(OH)3 in saline, i.p.
Day 3 and 7
Same dose as initial day
Day 15 histamine inhalation
Days 16–21 vehicle or steroid
Days 19 and 21 LPS (30 mg/ml)
inhalation
Day 21 OVA aerosol (300 mg/ml) 1
Day 22 Histamine inhalation
Allergen-induced bronchoconstriction: EAR (0–6 h) and LAR
(6–12 h)
OVA plus LPS increased the duration of EAR
AHR to histamine
Inflammatory cells in BALF
IL-13 and IL-17 in BALF
[102]
Both sexes, 300–350 g 100 μl of 2 mg OVA and 10
mg (AlOH3) in 10 ml saline, i.p.
Day 14
100 μl of 1 mg OVA in saline, i.p.
Days 21–30
1% OVA aerosol daily for 10min
Eosinophilia in blood
OVA-specific IgE
Oxidative stress markers in BALF
Collagen deposition
[184]
Male, Hartley strain, at 6 weeks of
age
Weeks 0 and 5
1 mg of nDer f 1,
10 mg of rDer f 2, or
10 mg of mite extract
plus 4.5 mg (AlOH3), and 1010
killed Bordetella pertussis s.c.
Weeks 3 and 7
1 mg of nDer f 1,
10 mg of rDer f 2, or
10 mg of mite extract
plus 4.5 mg (AlOH3), s.c.
Week 9
0.05 ml of either 10 mg/ml rDer
f 2 or mite extract solution, i.n.
* Mite extract-sensitized animals
were rechallenged with 0.05 ml of 30
mg/ml mite extract 15 min after the first
challenge
Early and late-phase cutaneous reaction
Allergen-induced bronchoconstriction, EAR (10–25 min)
Eosinophils in BALF
Plasma anti-mite IgE, IgG1, and IgG2
[109]
Male, Dunking-Hartley strain 0.25% HDM aerosol for
five consecutive days for 5min
0.5% HDM aerosol for
5 consecutive days for 5min
Day 14
skin prick test with 15 μl of 0.5% HDM;
i.d.
Early (weaker, in 4/10 guinea pigs) and late (stronger 10/10
guinea pigs)-phase cutaneous reaction
Cough, sneezes and nasal symptom during the EAR
No AHR to histamine or methacholine
[108]
Male, Hartley strain, 200–250 g 0.05, 0.5 or 2.5 mg/ml of cockroach
extract aerosols for 45 min, twice a day,
5 days a week, for a period of 4 weeks
Allergen-induced bronchoconstriction
Allergen-induced contractile response of tracheal rings
Inflammatory cells in BALF
Anaphylactic antibodies (IgE, IgG1)
Acetylcholine-induced contractile response of tracheal rings.
No AHR in vivo
[110–112]
Female, Hartley strain, 200–300 g Day 1
100 μ1 of 0.3 or 30% TMA in
corn oil, i.d.
Days 3 and 5
Same dose as initial day
Three weeks after sensitization
4 mg of TMA-GPSA, i.t. instillation
*Pyrilamine (6.1 mg/kg, i.p.)
Allergen-induced bronchoconstriction: EAR (10 min)
Inflammatory cells in BALF
Allergen-specific IgG1 and IgG2
Total protein and red blood cells in BALF
Complement activation product C3a in the BALF and plasma
EPO and MPO activity in BALF and lung tissue
[113,114,185,186]
Male, Dunkin–Hartley, 200–250 g Day 1
100 μ1 of 3 mg TMA in corn
oil, i.d.
Days 10 and 20
100 μ1 of 1 and 0.1 mg TMA in
corn oil, i.d.
Days 30–34
0.15 or 0.03% of TMA-GPSA, aerosols
for 15min
Day 35
250 μg TMA-GPSA in 50 μl PBS, i.t.
*Pyrilamine (10 mg/kg, i.p.)
EAR is reduced in repeated low dose of allergen
Inflammatory cells in BALF
AHR to acetylcholine at low allergen dose
Reduction in cysLTs, and TXB2 levels in BALF but enhanced
capacity to produce cysLTs, and TXB2 in vitro at low dose
allergen
[187]
Dunkin–Hartley guinea pigs correspond to the HsdDhl: DH colony, whereas Hartley guinea pigs correspond to the Crl:HA colony. Abbreviations: BALF, bronchoalveolar lavage; EAR, early asthmatic response; HDM, house dust
mite; i.d., intradermal; i.n., intranasal; i.p., intraperitoneal injection; i.t., intratracheal; LAR, late asthmatic response; LPS, lipopolysaccharide; OVA, ovalbumin; s.c., subcutaneous injection; TMA, trimellitic anhydride; TMA-GPSA;
TMA conjugated to guinea pig serum albumin.
*Denotes pharmacological treatment before challenge.
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intermittent allergen aerosols without a clear sensitization phase. The sensitization phase primes the immune sys-
tem to initiate an allergic inflammation with no visible reactions or symptoms. The challenge phase elicits an acute
reaction manifested by a temporal bronchospasm or EAR. One goal has been to create a model that expresses LAR,
which also has been reported in certain studies [26,102,106,115] (the latter discussed in [116]). However, several
studies have also described that allergic guinea pigs have no noticeable LAR [39,106,117]. Indeed, bronchoconstric-
tion induced by allergen provocation is variable in guinea pigs [118,119], similar to asthmatic humans [120,121]. It is
possible that the outbred nature of the guinea pigs influence reproducibility and that seasonal oscillation occur, but
to our knowledge this has not been verified. In guinea pig models, the heterogeneity of physiological and immuno-
logical responses has been primarily associated with the sensitization method and the allergen dose [100,101,122]. In
addition, other factors such as anesthesia and use of antihistamines to prevent anaphylaxis may similarly play a role
[18]. Accordingly, guinea pig elicits different patterns of allergic reactions. For instance, Yasue et al. found that the
allergic airway reaction provoked with rDer f 2 was higher than with whole mite extract, nevertheless, a further mite
extract-challenge increased the airway resistance in a dose-dependent manner [109]. Interestingly, in the aforemen-
tioned study, only 50% of the guinea pigs showed an immediate airway reaction, whereas 87% revealed an immediate
cutaneous reaction with erythema towards both allergens [109].
Guinea pigs unresponsive to allergen challenges are frequently not included in the studies [26,109,123], even
though these subjects might outline a similar phenotype to that observed in humans. A recent study showed that
guinea pigs with no allergen-induced bronchoconstriction do develop AHR and specific IgG1 responses [107]. Thus
far, the exact mechanisms of AHR in this particular model remain unclear; however, asymptomatic AHR in humans
has been described as a condition that may lead to asthma [124–126].
Avoidance of tolerance
A fine balance between allergen response and the induction of tolerance is a crucial phase in developing models
of allergic inflammation. To increase antigen immunogenicity, allergens are often adsorbed to adjuvants. For in-
stance, sensitization protocols with OVA often include aluminum compounds (Table 1) to evoke a TH2-dominant
bronchial response [127–130]. Likewise, Bordetella pertussis as adjuvant enhances the IgE production and rises
a long-lasting AHR [109,131–133]. Sulfur dioxide (SO2) enlarges OVA-induced EAR, eosinophilia, and antigen
specific-IgG1 [105,134]. This is an important finding since SO2 is a major air pollutant. In fact, other pollutants
suspended in the atmosphere may exacerbate the AHR or can act as adjuvants [135,136].
Developing experimental asthma protocols involves a complex interplay between immune tolerance and exacer-
bated responses. Therefore, the allergen dose is carefully considered in the protocols due to guinea pig sensitivity to
develop fatal anaphylaxis. Pre-treatment with antihistamines or bronchodilators is widely used to prevent an exac-
erbated bronchoconstriction [40,137–140], but may have effects on allergen-induced obstructive responses, inflam-
mation and AHR [18]. Conversely, antigen administration might also induce allergen unresponsive guinea pigs. To
avoid lacking response, increasing doses of allergen are administrated for long periods. This, in turn, results in thick-
ening of the airway wall with a residual and permanent airflow limitation, both hallmark features of chronic asthma
[141–143]. In this regard, continuous monitoring of lung parameters upon allergen challenge is an important ap-
proach to validate whether the experimental model does show the asthma-related pathophysiologic features, i.e. EAR
or LAR.
Exacerbation models
Infections are themost common cause of exacerbation in asthma. The dominating viruses are a specific picornavirus,
rhinovirus, followed by influenza/para influenza and respiratory syncytical virus [144,145]. Unlike guinea pigs, where
there are relatively few examples where asthma models have been exacerbated, there is a relatively large body of work
describing exacerbation of murine models of asthma (see reviews: [146,147]). In one study, sensitized guinea pigs
are inoculated with human parainfluenza-3 (hPIV-3) virus 5 days before ovalbumin challenge [148]. The presence
of hPIV-3 changed the time-course of airway obstruction induced by ovalbumin challenge. Instead of two relatively
transient phases, airway obstructionwasmuch longer lastingwith no discernible late phase. Airway obstruction, AHR
to histamine and elevated level of eosinophils in the BALwere all resistant to corticosteroid treatment. Comparedwith
challenge with ovalbumin alone, the presence of hPIV-3 elevated the numbers of neutrophils in the BAL.
As viral exacerbation of animal asthmamodels is difficult to replicate across different research groups, exacerbation
models using lipopolysaccharide (LPS) to mimic gram-negative bacterial stimulation (e.g. Haemophilus influenza)
have been developed [149]. The duration of the early phase of airway obstruction induced by allergen challenge was
increased by treatment with LPS. Although LPS had no significant effect on the magnitude or duration of late-phase
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airway obstruction, it did confer resistance to treatment with fluticasone propionate. LPS also made AHR to his-
tamine, and influx of leukocytes in the BAL resistant to fluticasone propionate. However, protein exudation into BAL
(an indirect measure of edema) was sensitive to fluticasone propionate indicating the lack of efficacy against other
parameters was not due to failure in delivery.
Modeling the cough reflex
In healthy subjects, coughing is part of a protective, airway sensory nerve-driven reflex designed to expel foreign
material from the lung. However, when this reflex becomes excessive and inappropriate, it develops into a clinical
problem, having a huge impact on people’s lives [150].
The guinea pig is an appropriate and necessary species for investigation into the mechanisms involved in normal
and chronic cough, and the search for novel, effective and safe therapies. While working with guinea pigs has cur-
rently some disadvantages compared with using rats and mice, e.g. the range of assays currently available is less and
genetic manipulation is challenging, they are solvable. Whereas, altering the sensory airway structure and function
in a mouse/rat to be more like man is not.
Modeling airway sensory nerve activity
In the search for new antitussive therapies, one approach is to work toward understanding the mechanisms by which
cough is initiated and propagated in healthy subjects, and then how this can change in respiratory diseases. To do this
one requires appropriate systems for the investigations. Typically, preclinical investigations are performed in guinea
pigs, as unlike mice and rats, they possess the cough reflex and their airways sensory nerves share similar structural
and functional features to humans [151]. Like healthy subjects, naı¨ve guinea pigs do not cough spontaneously. They
can, however, be induced to cough by exposing them to an aerosol of tussive solutions like the extract from chilli
peppers (capsaicin), or citric acid. Indeed, these are the same solutions that are used to trigger coughing in man
[152]. Furthermore, it is possible to model respiratory diseases in the guinea pig and then demonstrate they have an
altered sensitivity to inhaled tussive agents. This modification in cough responses parallels the change in phenotype
observed in patients with respiratory disease, for example it has be shown that patients with the smoking related
disease, COPD, have an increased cough response to capsaicin challenge. In a parallel cigarette smoke-driven model,
the guinea pigs cough more to the capsaicin challenge compared with the sham controls [152]. These in vivo systems
allow one to study cough sensitivity and the actions of potential antitussive therapies.While work is ongoing, one issue
with these model systems is that even with respiratory disease modeled in the guinea pig, they do not spontaneously
cough. Thus, replicating the clinical condition exactly is proving difficult and selecting an appropriate tussive stimuli
to profile new therapies can be problematic.
Studies of single airway sensory nerves in vivo
Other issues with using the whole animal cough system include: the large number of animals required (often need
n of 8–12 to obtain statistical significance with a 50% change); the need for appropriate tools for in vivo work and
the issues with being able to investigate details of the mechanisms, e.g. the type of sensory nerve fibre involved. To
address the latter issue, an in vivo system to record single airway sensory nerve firing has been developed [153,154].
While this system is a challenge to master and takes a great deal of time, it is essential for preclinical research. To
circumvent some of the other issues, parallel systems have been employed (reviewed recently by Bonvini et al, [154]).
Briefly, one system used is to record tussive stimuli trigged depolarization of the isolated sensory nerve (housed in
the vagus) tissue. The vagal tissue can be divided into multiple pieces and repeatedly challenged with tussive stimuli
(with and without test therapy, if required). This reduces the numbers of animals used and does not require in vivo
ready tools. Another advantage of the isolated vagal system is it is also possible to do parallel investigations using
human vagal tissue. The data produced has a very similar profile to the guinea pig vagus nerve and thus enables the
generation of translational data for targets of interest [152].
Like in humans, airway sensory nerve cell bodies are contained in jugular and nodose ganglia; rats and mice do
not have separate ganglia. It is possible to harvest and isolate airway neurones from these ganglia for investigations
[155]. As with the vagal systems, it is possible to examine the function of these cells (for example by tracking Ca2+
flux and changes in membrane potential, 8). In parallel, target expression patterns can be established at the mRNA
and protein level using techniques such as RT-PCR and immunohistochemistry [156]. A big advantage of using these
primary neurones, as with the vagal tissue, over configured cell-based systems is the fact that one is using innate
receptors/ion channels that are appropriately coupled to native, in vivo relevant functional machinery/proteins. Fur-
thermore, the growing body of data shows that the neurons (and the vagal tissue) harvested from respiratory disease
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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models, maintains the change in phenotype observed in vivo (and in the case of human vagus nerve, in the patient
group). For example, the vagus nerve and neurones harvested from the guinea pig model of COPD, exhibit a larger
ex vivo response to capsaicin challenge compared with the sham controls – paralleling the cough observation). The
fact that the phenotypic change is maintained ex vivo should aid the investigation into the mechanisms.
Opportunities and limitations
The guinea pig as a model species has great potential, however, the strength of an experimental model is not only
defined by its translatability to the human physiology and pathology, even more crucial is the ability to analyze such
a model. As comprehensively described above, the guinea pig can be used to study many physiological (e.g. cough,
AHR, EAR and LAR), histological (e.g. eosinophilia and airway remodeling,) pharmacological (drug discovery and
validation), immunological (e.g. immune cell infiltration and differentiation, and cytokine expression) processes.
However, guinea pig research is still restricted by the lack of guinea pig-specific reagents and chemicals. Especially
compared with human and more conventional laboratory animal species, such as mouse and rat, the availability of
reagents and specific tools suitable for guinea pig research is limited. Consequently, the interest to develop more
advanced models using natural allergens, that also affect for example the mucosal immunity, has not much been
applied in the guinea pig.
For decades, researchers’ willingness to spend time, effort andmoney has been the key driver in establishing suitable
reagents for guinea pig research, not only by adapting human, mouse or rat specific reagents, but even by developing
guinea pig-specific arrays [157–159]. Although the costs for guinea pigs usually are five times more than for mice or
rats, and with additional higher costs for housing, this needs to be offset by the greater relevace of the experimental
data. as outlined in this review. Researchers’ actions have led to an increase in commercially available guinea pig
specific reagents, and undertakings such as The Guinea Pig Genome Project by The Broad Institute greatly improve
guinea pig research. In the past efforts have been made to gather the information spread throughout the field of
guinea pig research, as greatly exampled by Lasco et al. paper on translatable guinea pig markers [160] and Scha¨fer
andBurger’s overview of the development of guinea pigmonoclonal antibodies [161]. In this paper, a similar effort has
beenmade to compose a repository of guinea pig tools that can be used in asthma research, for ELISA (Supplementary
Table S1), for flow cytometry (Supplementary Table S2), for immunohistochemistry (Supplementary Table S3) and
for PCR (Supplementary Table S4).
Gene-editing of the guinea pig genome
In a complex disease such as asthma many genes and their products interact for the manifestation of the disease.
Certain genes can be crucial for the etiology of the diseasewhereas others are important for the cardinal characteristics
of airway inflammation, bronchial reactivity and tissue remodeling. The introduction of genetically modified mice at
the end of the 1980s revolutionized medical research. With the development of the techniques during the following
decades it has become possible to ‘knock-out’ or ‘knock-in’ genes in a tissue/cell and time-specific manner. However,
gene-modified guinea pigs have yet not entered the scene. The main reason has been a lack of embryonic stem cells
preventing homologous recombination-based knockout approaches. Moreover, detailed knowledge of the guinea pig
genome came quite late, in the beginning of this century, and it was not, until this achievement, possible to identify
genes of interest in greater detail. With the rapid developments in genomics and CRISPR/Cas9 technology for gene
editing, it is now time to take the opportunity to use gene-editing of the guinea pig genome to generate animals that
can be used in experimental models to decipher the pathophysiology of asthma.
The guinea pig genomewas sequenced as part of theMammalianGenome Project funded by theNational Institutes
of Health and performed at the Broad Institute, Cambridge MA. It was originally sequenced at a low coverage, 2×,
but was in 2008 sequenced to 7× coverage with 95.55% of the bases assembled. The guinea pig genome is provided
by the UCSC genome browser (http://hgdownload.cse.ucsc.edu/downloads.html#guinea pig) or through Ensembl
(http://www.ensembl.org/Cavia porcellus/Info/Index?db=core). Although the high-coverage, 7×, ensure increased
accuracy for genome analysis it might be necessary to increase the coverage further, e.g., by PacBio assembly to reach
30× and>99% accuracy, especially for the analysis of immunoregulatory genes and other complex regions of interest
for asthma research. In addition to the original sequence of Cavia porcellus the genome of Cavia aperea is now also
sequenced and available. Furthermore, the Guinea Pig Genome Project at Broad is planning to obtain low coverage
of additional guinea pig strains (https://www.broadinstitute.org/guinea-pig/guinea-pig-genome-project).
With the sequence of the guinea pig genome available, it is possible to identify orthologs to human genes of interest
for asthma research. In addition to investigating the expression of genes by PCR or RNA sequencing, we also have
the opportunity to generate genetically modified guinea pigs for in vivo experiments. The CRISPR/Cas9 genome
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editing technique, which is adapted from an innate immune defense system that bacteria use against viruses, was
first proposed in 2012 [162] and has in a few years changed the possibility to edit genomes. The clustered regularly
interspersed short palindromic repeats (CRISPR) associated protein 9 (CRISPR/Cas9) technique is much quicker
and less expensive than traditional approaches. It also allows the generation of complex models with large deletions,
inversions, duplications or mutations in multiple genes. Already several publications have reported the use of this
technique to introduce mutations in domestic animals, including pigs, sheep, cattle and goats, but also in ferrets, fish
and other animals [163]. Considering the cost-benefit aspects for generating gene-edited guinea pigs, there are no
other reasons to not explore how experimentalmodels withmodified guinea pigs can contribute to our understanding
of asthma.
Drug development aspects
Despite large investments in drug development, drug attrition remains a problem across all therapeutic areas includ-
ing respiratory. The average number of new drugs approved by the U.S. Food and Drug Administration (FDA) per
year has declined since the 1990s, and only approximately 1 in 10 drugs that enter clinical phases makes it through to
FDA approval. The biggest attrition is in Phase II, where the success rate is 29% for respiratory indications within the
2006–2015 timeframe [164]. Whereas safety issues constitute the major reason for project closure preclinically and
in Phase I, lack of efficacy is by far the most dominating factor in Phase IIa and IIb failures [165]. One contributing
explanation is that the current use of animal models in preclinical research fail to bridge the translational gap to the
clinic.
Animal models have been and remain a cornerstone in drug discovery and are primarily used to [1] build con-
fidence in the target and its link to disease (predict clinical efficacy), [2] provide a clear understanding of the phar-
macokinetics/pharmacodynamics (PK/PD) relationship including demonstration of target engagement (predict dose
to man) and [3] establish clear safety margins (predict clinical safety). However, whereas the use of animal models
for establishing PK/PD relationships and safety margins is standard procedure, the contribution of current animal
models to target validation and prediction of therapeutic effect in patients is far more debatable in light of the high
clinical failure rate due to lack of efficacy.
When modeling aspects of human diseases, it becomes essential to select test species that are relevant for the re-
search questions at hand in relation to humandisease biology. The guinea pig offers a number of unique characteristics
thatmake it suitable as a small animal species for preclinical studies related to asthma andCOPD. Receptor andmedi-
ator pharmacology are comparable with the human situation, the anatomy and physiology of the guinea pig lung are
similar to that of humans and the airway innervation of guinea pig airways is also similar to that of humans [7,152].
Furthermore, the airway response to allergen challenge in guinea pigs involves both early and late allergic responses,
which makes it similar to that in humans and very different from that in mice [26]. Mice are easily bread, highly
amenable to genomic manipulation [166] with a wide array of specific reagents available for analysis of the cellular
and mediator response. For these reasons mice have become the preferred test system also for preclinical respiratory
research, which is unfortunate as for most endpoints, guinea pig models of asthma and COPD are superior [167]. To
narrow the translational gap between preclinical models of asthma and COPD and human disease biology, the guinea
pig needs to be resurrected as an important test species.
For this to happen though, the apparent disadvantages of using guinea pigs need to be addressed and resolved.
One important area will be to enable efficient generation of gene-modified guinea pigs (see above). The ease by
which genes can be knocked out or knocked in in mice has been a major driver of the explosive increase in the use
of mice in preclinical research. Guinea pig genetics is certainly more challenging than mouse genetics due to their
significantly lower reproduction rate, but the prospects for transgenic animals are improving with the introduction
and implementation of new technology. Another blocker to using guinea pigs for preclinical research has been the
limited availability of reagents including antibodies for immunoassays and immunohistochemistry. A renewed inter-
est in guinea pigs as a test species would drive a demand for tools, which in turn would automatically start build a
commercial supply of such reagents. In addition, implementation of new technologies such as RNA sequencing and
RNAscope in situ hybridization offers new analytical opportunities.
Future perspectives
The reason to develop a model of asthma is to identify the mechanisms with relevance to the disease and to define
pharmacological treatments. As the knowledge of themechanisms are not fully defined, themodel development aims
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to mimic specific features and criteria typical for asthma of which the main are airway obstruction, chronic inflam-
mation and the remodeling. However, this is complicated because these criteria may have different requirements for
distinct asthma phenotypes.
Allergic asthma is a common phenotype and the development of models has therefore focused on different strate-
gies to mimic this. In the earlier models, OVA was the dominant allergen of choice. The exchange from OVA to
clinically relevant allergens in murine models has demonstrated more composite immunological reactions compared
with OVA [168]. The airway reactions to natural allergens are complex and starts at the site of the airway epithe-
lium. The natural allergens are not only composed of the epitopes that are detected by IgE, but also molecules that
in different manners trigger or damage the epithelium that makes them to serve as adjuvants for allergic reaction.
The adjuvant reaction has shown to be induced by specific activation of the innate immunological defense system.
In parallel with the innate response, the adaptive reaction through dendritic cells to engulf the molecules that subse-
quently will end up being presented as antigen will take place. Thus, the model development in guinea pigs may be
much improved using clinically relevant allergens and relevant routes of exposure.
The switch to natural allergen, has in many mouse models indicated that the sensitization phase should also be
performed through airway exposure. As aerosol inhalations can be expensive when using natural allergens, it would
be attractive to use intranasal instillation that is commonly performed in mice during a short isoflurane anesthesia.
Intranasal instillation can be performed in guinea pigs but is technically challenging without anesthesia and compli-
cated because the guinea pig is more difficult to anesthetize. Moreover, due to the big nasal cavity, the amount that
reaches the lung can be more variable. Thus, the procedure for airway administration needs to be further developed
into practical solutions that both are reliable and reproducible.
In the guinea pig allergic model of asthma, it is always possible to measure EAR. This is almost impossible to
perform in mice. The EAR confirms a successful IgE activation and response, and can therefore be an important
parameter for intervention studies. Non-invasive methods for measurement can be used to follow the IgE responses
during the protocol. The LAR is a more difficult parameter to study due to the time needed to detect this and the
inherent individual-to-individual temporal variabilty. However, there are several studies showing this in guinea pig
models [26,102,106,115], whereas it is practically unfeasible to study in mice.
One objective for an asthma model is to allow studies of AHR. The AHR can be evaluated using direct acting
agonists, such as histamine, muscarinic agonists and CysLTs, or indirect acting agonists, such as adenosine and man-
nitol [117,133,137,169]. This is clearly exemplified by the hyperresponsivity to inhaled adenosine in allergic guinea
pigs [170]. In contrast, administration of muscarinic receptor agonists is almost the only agent that can be used in
mice. An increasing awareness of the importance of the small airways in asthma has caused an increased interest for
lung function measurement that separate the proximal and distal responses of the airways. The technique for doing
these measurements has successfully been developed in mice using FOT, whereas it has almost never been used in
guinea pig. It is possible that a different pattern of responses will be observed in guinea pigs compared with mice as
the guinea pig has smooth muscle cells surrounding all branches down to the distal airways, whereas mice have no
smooth muscle beyond large airways [73].
Further suggestions for the future
When the additional tools for investigation of the guinea pig asthma models have been established, there are several
exciting possibilities for discoveries. If the use of the animal increases, the interest to developmore tools will increase.
Having better tools, more researchers will be using the animal and a virtuous circle will be established. With the cur-
rent clinical insight into asthma phenotypes, there is already a great need for asthma models of different phenotypes,
e.g. non-TH2 types of asthma, as well as the role of co-morbidities such as obesity. As guinea pigs share so many
pulmonary features with humans, it is possible that this species has an explicit potential to be used for developing
other phenotypes. We believe that guinea pig models will be important for further asthma studies into exacerbations,
the role of the microbiome, epigenetic regulation, and impact of gender and age. Of particular relevance to the use
of guinea pigs is the study of early onset asthma, as it is easier to study pups from guinea pigs than from mice. With
an increased use, and an increased demand for breeding it is possible that inbreed strains will be created. With this,
geneticallymodified guinea pigs also can eventually be generated. It is clear we are a long way from reaching the limits
of what is possible using guinea pig models and realising their full potential.
As described in this review, there are many defined advantages to the use of guinea pigs in asthma research. Yet,
there is also a requirement for more development to make models in this animal more effective, especially in regards
to studies on inflammation, immunology and those that require genetically modified guinea pigs. In particular, the
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guinea pig has a distribution of mast cells that is similar to humans, which should attract the researcher as mouse
models fail tomimic the interactions between other inflammatory cells andmast cells that are fundamental in asthma.
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